Immunic Inc. (10VA)
XMUN 
Summary
10VA Chart
Immunic to host virtual relapsing MS R&D Day on September 9
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating
Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunic Inc. (10VA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunic Inc. ever had a stock split?
Immunic Inc. Profile
| Biotechnology Industry | Healthcare Sector | Erik Lundgren CEO | XMUN Exchange | US4525EP2001 ISIN |
| US Country | 100 Employees | 15 Apr 2019 Last Dividend | 27 Apr 2026 Last Split | 17 Apr 2014 IPO Date |
Overview
Immunic, Inc. is a biotechnology company with a core focus on the development of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Established in 2016 and with operations in both the United States and Germany, Immunic, Inc. dedicates itself to advancing a pipeline of novel treatments that promise a brighter future for patients suffering from these debilitating conditions. By targeting the underlying causes of such diseases, Immunic strives to deliver effective and innovative medical solutions that can improve the quality of life for those affected.
Products and Services
- IMU-838 - This leading drug candidate is currently in Phase 3 clinical trial stages, focusing on the treatment of multiple sclerosis, including both relapsing and progressive types, as well as moderate-to-severe ulcerative colitis. IMU-838 represents Immunic, Inc.'s commitment to addressing auto-immune challenges through selective oral immunology therapies, targeting a critical need in the management of auto-immune and inflammatory diseases.
- IMU-856 - Poised to enter Phase 2 clinical trials, IMU-856 is being developed as a solution for the restoration of intestinal barrier function in patients suffering from a variety of gastrointestinal diseases. These include celiac disease, inflammatory bowel disease, short bowel syndrome, and irritable bowel syndrome with diarrhea, among others. This product focuses on restoring the natural defense mechanisms of the gastrointestinal tract, which is a novel approach to treating these conditions.
- IMU-381 - Still in the preclinical trial phase, IMU-381 is designed to target gastrointestinal diseases, with a focus on a new method of treatment. Although details about its specific action are less advanced than those of IMU-838 and IMU-856, IMU-381 represents Immunic, Inc.'s ongoing efforts to expand its portfolio and tackle a broader range of inflammatory and autoimmune diseases through innovative therapeutic approaches.
